Gladstone Institutional Advisory LLC Raises Stock Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Gladstone Institutional Advisory LLC boosted its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 7.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 154,249 shares of the company’s stock after acquiring an additional 10,310 shares during the quarter. Gladstone Institutional Advisory LLC’s holdings in Teva Pharmaceutical Industries were worth $3,400,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the business. Smithfield Trust Co raised its stake in shares of Teva Pharmaceutical Industries by 55.7% during the third quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock valued at $50,000 after acquiring an additional 980 shares in the last quarter. Wilmington Savings Fund Society FSB purchased a new position in Teva Pharmaceutical Industries during the 3rd quarter worth $50,000. Claro Advisors LLC bought a new stake in Teva Pharmaceutical Industries during the 3rd quarter valued at $52,000. Venturi Wealth Management LLC purchased a new stake in shares of Teva Pharmaceutical Industries in the 3rd quarter worth $60,000. Finally, Ameliora Wealth Management Ltd. bought a new position in shares of Teva Pharmaceutical Industries during the 4th quarter worth $66,000. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Insiders Place Their Bets

In related news, Director Roberto Mignone sold 286,000 shares of the firm’s stock in a transaction on Friday, December 20th. The stock was sold at an average price of $22.01, for a total value of $6,294,860.00. Following the completion of the transaction, the director now owns 695,000 shares in the company, valued at $15,296,950. This trade represents a 29.15 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Christine Fox sold 19,388 shares of Teva Pharmaceutical Industries stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total value of $327,075.56. Following the sale, the executive vice president now directly owns 44,104 shares of the company’s stock, valued at approximately $744,034.48. This represents a 30.54 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.55% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently weighed in on TEVA. StockNews.com downgraded Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 18th. UBS Group reduced their price target on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating for the company in a report on Thursday, January 30th. Piper Sandler increased their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a research note on Friday, January 17th. JPMorgan Chase & Co. boosted their price objective on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a research note on Monday, October 21st. Finally, Barclays lowered their target price on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a report on Thursday, January 30th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $23.57.

Teva Pharmaceutical Industries Stock Performance

NYSE:TEVA opened at $16.33 on Thursday. The firm has a 50 day moving average of $20.04 and a 200 day moving average of $18.52. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.61. Teva Pharmaceutical Industries Limited has a 52 week low of $12.51 and a 52 week high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, beating the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. As a group, research analysts predict that Teva Pharmaceutical Industries Limited will post 2.62 earnings per share for the current fiscal year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.